Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT

Bone Marrow Transplantation volume 29, pages 577–580 (2002)Cite this article

Abstract

Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy. PBSCT is considered standard treatment for most patients requiring therapy for MM; however, patients with VAD-resistant disease may not be able to receive PBSCT due to rapidly advancing disease. We report four cases of VAD-refractory MM salvaged with THAL + VAD followed by PBSCT. All patients underwent stem cell mobilization with cyclophosphamide (Cy) (4.5 g/m2) and GMCSF. Melphalan (140–200 mg/m2) was given as conditioning. All patients engrafted within 12–16 days after PBSCT. Day +100 evaluation showed the following: very good partial response (n = 1) and complete response (n = 3). After a median follow-up to 153 days, two patients continue to take THAL with no signs of disease progression. One patient developed CHF and was taken off THAL while another patient has died of progressive disease while on THAL (MTD 50 mg). In conclusion, VAD-refractory patients were salvaged with the addition of THAL to VAD. They were subsequently able to undergo autologous PBSCT for MM, which will likely improve their overall survival. This suggests that THAL and other related immunomodulatory drugs may prove useful for initial MM therapy in combination with standard chemotherapy followed by PBSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents New Engl J Med 1984 310: 1353 1356

    Article  CAS  Google Scholar 

  2. Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma Lancet 1989 2: 882 885

    Article  CAS  Google Scholar 

  3. Kantarjian H, Dreicer R, Barlogie B et al. High dose cytosine arabinoside in multiple myeloma Eur J Clin Oncol 1984 20: 227 231

    Article  CAS  Google Scholar 

  4. Ganjoo RK, Williams A, Malpas J . Vincristine and oral etoposide in refractory multiple myeloma Cancer Chemother Pharmacol 1995 35: 343 344

    Article  CAS  Google Scholar 

  5. Barlogie B, Velasquez WS, Alexanian R et al. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma J Clin Oncol 1989 7: 1514 1517

    Article  CAS  Google Scholar 

  6. Dimopoulos MA, Weber D, Kantarjian H et al. Hyper CVAD for VAD-resistant multiple myeloma Am J Hematol 1996 52: 77 81

    Article  CAS  Google Scholar 

  7. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma New Engl J Med 1999 341: 1565 1571

    Article  CAS  Google Scholar 

  8. Juliusson G, Celsing F, Malm C et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma Br J Haematol 2000 109: 89 96

    Article  CAS  Google Scholar 

  9. Rajkumar S, Fonseca R, Dispenzieri A et al. Thalidomide in the treatment of relapsed multiple myeloma Mayo Clin Proc 2000 75: 897 901

    Article  CAS  Google Scholar 

  10. Kneller A, Raanani P, Ben-Bassat I et al. Therapy with thalidomide in refractory multiple myeloma patients – the revival of an old drug Br J Haematol 2000 108: 391 393

    Article  CAS  Google Scholar 

  11. Durie BGM, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival Cancer 1975 36: 842 854

    Article  CAS  Google Scholar 

  12. Hales BF . Thalidomide on the comeback trail Nat Med 1999 5: 489 490

    Article  CAS  Google Scholar 

  13. Corral LG, Haslett PAJ, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α J Immunol 1999 163: 380 386

    CAS  PubMed  Google Scholar 

  14. Tosi P, Ronconi S, Zamagni E et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation Haematologica 2001 86: 409 413

    CAS  PubMed  Google Scholar 

  15. Zomas A, Anagnostopoulos N, Dimopoulos MA . Successful treatment of multiple myeloma relapsing after high dose therapy and autologous transplantation with thalidomide as a single agent Bone Marrow Transplant 2000 25: 1319 1320

    Article  CAS  Google Scholar 

  16. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 2000 96: 2943 2950

    CAS  Google Scholar 

  17. Weber DM, Gavino M, Delasalle K et al. Thalidomide alone or with dexamethasone for multiple myeloma Blood 1999 94: 604a

    Google Scholar 

  18. Barlogie B, Desikan R, Munshi N et al. Single course DTPACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma Blood 1998 92: 273b

    Google Scholar 

  19. Munshi N, Desikan R, Zangari M et al. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma Blood 1999 94: 123a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA

    I Ahmad, T Islam, A Chanan-Khan, T Hahn, D Wentling, JL Becker, PL McCarthy Jr & AR Alam

Authors
  1. I Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Chanan-Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Wentling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JL Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. PL McCarthy Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. AR Alam
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmad, I., Islam, T., Chanan-Khan, A. et al. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant 29, 577–580 (2002). https://doi.org/10.1038/sj.bmt.1703522

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703522

Keywords

This article is cited by

Search

Advanced search

Quick links